ReviewVaccines2022
COVID-19-Associated Mucormycosis: A Matter of Concern Amid the SARS-CoV-2 Pandemic.
Review in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 29 citations in OpenAlex.
- Breakthrough mucormycosis after hematopoietic stem cell transplantation: a retrospective multiyear cohort study in Eastern China.Annals of clinical microbiology and antimicrobials · 2026Observational
- Survival and renal outcomes of mucormycosis infection and its treatment regimens in resource-limited settings: a retrospective case series.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Correlation Between Endoscopic and Radiological Data in Rhino-Orbital-Cerebral Mucormycosis (ROCM).Cureus · 2026Article
- A novel mannan-specific chimeric antigen receptor M-CAR redirects T cells to interact withBioengineered · 2025Article
- Exploring the therapeutic potential of Thymus vulgaris ethanol extract: a computational screening for antimicrobial compounds against COVID-19 induced mucormycosis.Scientific reports · 2025Article
- Review
- Cutaneous mucormycosis in systemic lupus erythematosus: a case report.Frontiers in immunology · 2025Article
- Molecular architecture of chitin and chitosan-dominated cell walls in zygomycetous fungal pathogens by solid-state NMR.Nature communications · 2024Article
- A global perspective of the changing epidemiology of invasive fungal disease and real-world experience with the use of isavuconazole.Medical mycology · 2024Review
- Corona-Associated Mucormycosis: Case Series Reports and Review of the Literature.Journal of fungi (Basel, Switzerland) · 2024Article
- Hand contamination and hand hygiene knowledge and practices among commercial transport users after the SARS-CoV-2 virus (COVID-19) scare, Enugu State, Nigeria.PLOS global public health · 2024Article
- Invasive Fungal Infections Associated with COVID-19.Journal of fungi (Basel, Switzerland) · 2023Review
- Antifungal Drug Resistance: An Emergent Health Threat.Biomedicines · 2023Review
- A peek behind the curtain in the diagnosis and management of COVID‑19‑Associated Mucormycosis (CAM).The Journal of the Egyptian Public Health Association · 2023Review
- Rise of mucormycosis during the COVID-19 pandemic and the challenges faced.Current medical mycology · 2023Review
- Addressing Microbial Resistance Worldwide: Challenges over Controlling Life-Threatening Fungal Infections.Pathogens (Basel, Switzerland) · 2023Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Mucormycosis is an invasive fungal infection caused by fungi belonging to order Mucorales. Recently, with the increase in COVID-19 infections, mucormycosis infections have become a matter of concern globally, because of the high morbidity and mortality rates associated with them. Due to the association of mucormycosis with COVID-19 disease, it has been termed COVID-19-associated mucormycosis (CAM). In the present review, we focus on mucormycosis incidence, pathophysiology, risk factors, immune dysfunction, interactions of Mucorales with endothelial cells, and the possible role of iron in Mucorales growth. We review the limitations associated with current diagnostic procedures and the requirement for more specific, cost-effective, convenient, and sensitive assays, such as PCR-based assays and monoclonal antibody-based assays for the effective diagnosis of mucormycosis. We discuss the current treatment options involving antifungal drug therapies, adjunctive therapy, surgical treatment, and their limitations. We also review the importance of nutraceuticals-based therapy for the prevention as well as treatment of mucormycosis. Our review also highlights the need to explore the potential of novel immunotherapeutics, which include antibody-based therapy, cytokine-based therapy, and combination/synergistic antifungal therapy, as treatment options for mucormycosis. In summary, this review provides a complete overview of COVID-19-associated mucormycosis, addressing the current research gaps and future developments required in the field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.